RXO INC (RXO) Fundamental Analysis & Valuation

NYSE:RXO • US74982T1034

Current stock price

19.09 USD
+1.11 (+6.17%)
Last:

This RXO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. RXO Profitability Analysis

1.1 Basic Checks

  • RXO had negative earnings in the past year.
  • In the past year RXO had a positive cash flow from operations.
  • In multiple years RXO reported negative net income over the last 5 years.
  • RXO had a positive operating cash flow in 4 of the past 5 years.
RXO Yearly Net Income VS EBIT VS OCF VS FCFRXO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M 300M

1.2 Ratios

  • RXO's Return On Assets of -3.05% is on the low side compared to the rest of the industry. RXO is outperformed by 66.67% of its industry peers.
  • Looking at the Return On Equity, with a value of -6.49%, RXO is doing worse than 64.29% of the companies in the same industry.
Industry RankSector Rank
ROA -3.05%
ROE -6.49%
ROIC N/A
ROA(3y)-3.78%
ROA(5y)0.09%
ROE(3y)-7.94%
ROE(5y)1.18%
ROIC(3y)N/A
ROIC(5y)N/A
RXO Yearly ROA, ROE, ROICRXO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 10 -10

1.3 Margins

  • Looking at the Gross Margin, with a value of 16.39%, RXO is doing worse than 71.43% of the companies in the same industry.
  • In the last couple of years the Gross Margin of RXO has declined.
  • The Profit Margin and Operating Margin are not available for RXO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 16.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.99%
GM growth 5Y-2.2%
RXO Yearly Profit, Operating, Gross MarginsRXO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 5 -5 10 15

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. RXO Health Analysis

2.1 Basic Checks

  • RXO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for RXO has been increased compared to 1 year ago.
  • RXO has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for RXO is higher compared to a year ago.
RXO Yearly Shares OutstandingRXO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 50M 100M 150M
RXO Yearly Total Debt VS Total AssetsRXO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • An Altman-Z score of 2.71 indicates that RXO is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • RXO has a Altman-Z score (2.71) which is in line with its industry peers.
  • A Debt/Equity ratio of 0.25 indicates that RXO is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.25, RXO is in line with its industry, outperforming 57.14% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z 2.71
ROIC/WACCN/A
WACC10.49%
RXO Yearly LT Debt VS Equity VS FCFRXO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 1.27 indicates that RXO should not have too much problems paying its short term obligations.
  • The Current ratio of RXO (1.27) is comparable to the rest of the industry.
  • RXO has a Quick Ratio of 1.27. This is a normal value and indicates that RXO is financially healthy and should not expect problems in meeting its short term obligations.
  • RXO has a Quick ratio of 1.27. This is comparable to the rest of the industry: RXO outperforms 59.52% of its industry peers.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.27
RXO Yearly Current Assets VS Current LiabilitesRXO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. RXO Growth Analysis

3.1 Past

  • RXO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -145.45%.
  • The Revenue has grown by 26.20% in the past year. This is a very strong growth!
  • Measured over the past years, RXO shows a quite strong growth in Revenue. The Revenue has been growing by 11.33% on average per year.
EPS 1Y (TTM)-145.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.67%
Revenue 1Y (TTM)26.2%
Revenue growth 3Y6.18%
Revenue growth 5Y11.33%
Sales Q2Q%-11.88%

3.2 Future

  • RXO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 155.84% yearly.
  • RXO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.55% yearly.
EPS Next Y90.24%
EPS Next 2Y212.21%
EPS Next 3Y155.84%
EPS Next 5YN/A
Revenue Next Year-0.55%
Revenue Next 2Y3%
Revenue Next 3Y4.63%
Revenue Next 5Y9.55%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
RXO Yearly Revenue VS EstimatesRXO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2B 4B 6B 8B 10B
RXO Yearly EPS VS EstimatesRXO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 0 0.5 1

More info and screens

Find the best growth stocksShow best growing peers

1

4. RXO Valuation Analysis

4.1 Price/Earnings Ratio

  • RXO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RXO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXO Price Earnings VS Forward Price EarningsRXO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -1K -2K -3K

4.2 Price Multiples

  • 71.43% of the companies in the same industry are cheaper than RXO, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 30.72
RXO Per share dataRXO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • RXO's earnings are expected to grow with 155.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y212.21%
EPS Next 3Y155.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RXO Dividend Analysis

5.1 Amount

  • No dividends for RXO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RXO Fundamentals: All Metrics, Ratios and Statistics

RXO INC

NYSE:RXO (4/17/2026, 1:07:07 PM)

19.09

+1.11 (+6.17%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupTransportation
GICS IndustryGround Transportation
Earnings (Last)02-06
Earnings (Next)05-07
Inst Owners108.53%
Inst Owner Change0%
Ins Owners0.84%
Ins Owner Change2.22%
Market Cap3.14B
Revenue(TTM)5.74B
Net Income(TTM)-100.00M
Analysts66.92
Price Target16.4 (-14.09%)
Short Float %8.54%
Short Ratio5.67
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-75.97%
Min EPS beat(2)-79.64%
Max EPS beat(2)-72.3%
EPS beat(4)1
Avg EPS beat(4)-27.69%
Min EPS beat(4)-79.64%
Max EPS beat(4)101.04%
EPS beat(8)5
Avg EPS beat(8)-6.09%
EPS beat(12)8
Avg EPS beat(12)38.1%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2%
Min Revenue beat(2)-2.2%
Max Revenue beat(2)-1.8%
Revenue beat(4)0
Avg Revenue beat(4)-2.86%
Min Revenue beat(4)-5.04%
Max Revenue beat(4)-1.8%
Revenue beat(8)1
Avg Revenue beat(8)-1.36%
Revenue beat(12)2
Avg Revenue beat(12)-2.06%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.61%
EPS NQ rev (1m)-0.84%
EPS NQ rev (3m)-105.48%
EPS NY rev (1m)-136.02%
EPS NY rev (3m)-102.85%
Revenue NQ rev (1m)-0.07%
Revenue NQ rev (3m)-5.38%
Revenue NY rev (1m)-0.1%
Revenue NY rev (3m)-3.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.55
P/FCF N/A
P/OCF 61.65
P/B 2.04
P/tB N/A
EV/EBITDA 30.72
EPS(TTM)-0.05
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)0.31
OCFY1.62%
SpS34.86
BVpS9.36
TBVpS-0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -3.05%
ROE -6.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 16.39%
FCFM N/A
ROA(3y)-3.78%
ROA(5y)0.09%
ROE(3y)-7.94%
ROE(5y)1.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.99%
GM growth 5Y-2.2%
F-Score5
Asset Turnover1.75
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA 3.55
Cap/Depr 50.86%
Cap/Sales 1.03%
Interest Coverage N/A
Cash Conversion 46.79%
Profit Quality N/A
Current Ratio 1.27
Quick Ratio 1.27
Altman-Z 2.71
F-Score5
WACC10.49%
ROIC/WACCN/A
Cap/Depr(3y)66.04%
Cap/Depr(5y)62.51%
Cap/Sales(3y)1.22%
Cap/Sales(5y)1.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-145.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-216.67%
EPS Next Y90.24%
EPS Next 2Y212.21%
EPS Next 3Y155.84%
EPS Next 5YN/A
Revenue 1Y (TTM)26.2%
Revenue growth 3Y6.18%
Revenue growth 5Y11.33%
Sales Q2Q%-11.88%
Revenue Next Year-0.55%
Revenue Next 2Y3%
Revenue Next 3Y4.63%
Revenue Next 5Y9.55%
EBIT growth 1Y-123.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year133.6%
EBIT Next 3Y84.84%
EBIT Next 5Y60.59%
FCF growth 1Y85.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y525%
OCF growth 3Y-45.21%
OCF growth 5Y15.33%

RXO INC / RXO Fundamental Analysis FAQ

What is the fundamental rating for RXO stock?

ChartMill assigns a fundamental rating of 2 / 10 to RXO.


What is the valuation status for RXO stock?

ChartMill assigns a valuation rating of 1 / 10 to RXO INC (RXO). This can be considered as Overvalued.


How profitable is RXO INC (RXO) stock?

RXO INC (RXO) has a profitability rating of 1 / 10.


Can you provide the financial health for RXO stock?

The financial health rating of RXO INC (RXO) is 3 / 10.